Dorin Toader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dorin Toader has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Timothy B. Lowinger
Mersana Therapeutics, Inc., Cambridge, Massachusetts
106 shared publications - Kalli C. Catcott
Mersana Therapeutics, Inc., Cambridge, Massachusetts
105 shared publications - Ling Xu
Mersana Therapeutics, Inc., Cambridge, Massachusetts
105 shared publications - Marc Damelin
Mersana Therapeutics, Inc., Cambridge, Massachusetts
105 shared publications - Scott D. Collins
Mersana Therapeutics, Inc., Cambridge, Massachusetts
86 shared publications - Eugene Kelleher
Mersana Therapeutics, Inc., Cambridge, Massachusetts
82 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S3. HER2 expression in cell lines and tumor xenografts, including gene expression by RNAseq (log2 transformed); binding EC50 and maximal fluorescence intensity (Bmax FL) of XMT-2056 by flow cytometry, and HER2 immunohistochemistry in tumor xenografts. EC50 and Bmax values represent mean of 2 independent experiments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S3. HER2 expression in cell lines and tumor xenografts, including gene expression by RNAseq (log2 transformed); binding EC50 and maximal fluorescence intensity (Bmax FL) of XMT-2056 by flow cytometry, and HER2 immunohistochemistry in tumor xenografts. EC50 and Bmax values represent mean of 2 independent experiments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows TROP2 receptor quantification on DLD1 and HT29 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows TROP2 receptor quantification on DLD1 and HT29 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Structures of PBD Platform 5 and AF-HPA Platform 7 (known as Dolaflexin)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Structures of PBD Platform 5 and AF-HPA Platform 7 (known as Dolaflexin)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows Tabulated cell growth inhibition data for NCI-N87 and MDA-MB231 cells in monoculture and coculture when treated with ADCs T-16, T-17, and T-18
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows Tabulated cell growth inhibition data for NCI-N87 and MDA-MB231 cells in monoculture and coculture when treated with ADCs T-16, T-17, and T-18
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Extinction coefficient used to determine DAR for ADCs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Extinction coefficient used to determine DAR for ADCs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows Cytotoxicity Data for Platforms 18 vs 19
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Table shows Cytotoxicity Data for Platforms 18 vs 19
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S7. A. CB.17 SCID mice bearing subcutaneous JIMT-1 xenograft tumors were administered 3 weekly doses of XMT-2056, a combination of non-binding control ADC and pertuzumab, or a combination of XMT-2056 and pertuzumab. B. CB.17 SCID mice bearing subcutaneous SNU-5 xenograft tumors were administered a single dose of XMT-2056, non-binding control ADC, pertuzumab, or a combination of XMT-2056 and pertuzumab. ADCs were administered intravenously while pertuzumab was administered intraperitoneally. Each point represents the mean tumor volume and SEM (n=10).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S7. A. CB.17 SCID mice bearing subcutaneous JIMT-1 xenograft tumors were administered 3 weekly doses of XMT-2056, a combination of non-binding control ADC and pertuzumab, or a combination of XMT-2056 and pertuzumab. B. CB.17 SCID mice bearing subcutaneous SNU-5 xenograft tumors were administered a single dose of XMT-2056, non-binding control ADC, pertuzumab, or a combination of XMT-2056 and pertuzumab. ADCs were administered intravenously while pertuzumab was administered intraperitoneally. Each point represents the mean tumor volume and SEM (n=10).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Figure shows Plasma stability comparing indole-linked ADC T-13 to N10-linked ADC T-BH
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Figure shows Plasma stability comparing indole-linked ADC T-13 to N10-linked ADC T-BH
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Figure shows In vitro activity of NaPi2b ADCs X-BG and X-19 and payload 4 in the OVCAR3 cell line
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Figure shows In vitro activity of NaPi2b ADCs X-BG and X-19 and payload 4 in the OVCAR3 cell line
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates